Project description
Promising 'skins' created from a patient's own skin cells are moving through clinical trials
The primary function of the skin is protection from mechanical impact, temperature changes, microorganisms, chemicals and radiation. Millions of people worldwide suffer from severe skin damage and removing that critical barrier exposes them to dangerous pathogens. Surgical interventions such as skin grafts are often painful and plagued by scarring. Further, multiple surgeries may be necessary to address the damage. SkinFactory 2.0 has developed the technology to produce novel, bioengineered skin grafts from a patient's own cells. The grafts are currently in phase II clinical trials in Europe. EU funding is supporting the application of cutting-edge 'Good Manufacturing Practices (GMP)-in-a-box' technology for en masse production of autologous cell therapies, overcoming current methods limited to small quantities under the strictest GMP guidelines.
Objective
CUTISS AG is a Swiss start-up company that develops customized human skin autografts (denovoSkin™) for the treatment of large skin defects like burns and malformations. DenovoSkin™ possesses the right features to minimize scarring after transplantation and is currently in clinical phase II in Europe. While manual production of denovoSkin™ is sufficient in the development phase and clinical trials, automation of the manufacturing process is essential to scale the technology for larger demand and internationalization, and to be competitive with current standard treatments. The proposed recruitment of an Innovation Associate will have significant impact on the development of an automated system for the manufacturing of denovoSkin™ (SkinFactory 2.0) enabling production lines at industrial scale and around the world. The grant will help to overcome the recruitment barriers of being a relatively unknown, small start-up enterprise that cannot compete with larger companies due to limited visibility, brand awareness, (perceived) career opportunities, salary and recruitment budget. The translation of the manual production process of denovoSkin™ to an GMP-in-a-box automation platform requires the employment of a multi-disciplinary researcher that understands both the cell biology and complex requirements of tissue engineering as well as the mechatronics and industrial design of automation. The envisaged Innovation Associate has to bring a multidisciplinary set of skills in to CUTISS and will have the opportunity to become an expert in the emerging field of bio-engineering. It is in the interest of the company to continue the employment after the initial year in order to develop the delivered prototype into an industrially producible end product. Successful market introduction of SkinFactory 2.0 will put CUTISS in the forefront of a new, emerging field of automated production of personalized, bio-engineered tissue, which is expected to change medicine radically.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- engineering and technology electrical engineering, electronic engineering, information engineering electronic engineering control systems
- social sciences sociology industrial relations automation
- medical and health sciences medical biotechnology tissue engineering
- social sciences economics and business business and management employment
- medical and health sciences clinical medicine transplantation
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
H2020-EU.2.3. - INDUSTRIAL LEADERSHIP - Innovation In SMEs
MAIN PROGRAMME
See all projects funded under this programme -
H2020-EU.2.3.2.2. - Enhancing the innovation capacity of SMEs
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
CSA - Coordination and support action
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) H2020-INNOSUP-2018-2020
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
8006 Zurich
Switzerland
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.